The effect of the combination of antihypertensive and urate lowering therapy on vascular endothelial function in patients with hypertensive and asymptomatic hyperuricemia--A random ,open clinical trial

INTERVENTION: control group:anti‐hypertension and lifestyle change;invention group:anti‐hypertension, life style invention and Benzbronmarone; CONDITION: hypertension with asyptomatic hyperuricemia PRIMARY OUTCOME: the flow mediated dilation, FMD;Pulse wave velocity, PWV;endothelial Microparticles EM; SECONDARY OUTCOME: hyper‐ sensitivity C ‐reactive protein hs‐CRP;urinary microalbuminuria, UMA;atherogenic index of plasma, AI; INCLUSION CRITERIA: 1. participants with age between eighteen to sixty years old, male or female; 2. body mass index <30 kg/m2; 3. without treatment,or mild‐to‐moderate hypertension subjects with anti‐hypertensive agents(SBP from 140 to 180mmHg and DBP from 90 to 110mmHg); 4. serum uric acid level >420 umol/L (7 mg/dL); 5. participants must sign informed consent; 6. type of uric acid discharge poor: uric acid drainage less than 0.48 mg/kg/h, uric acid clearance (Cua, urinary uric acid * every minute urine volume/serum uric acid) < 6.2 ml/min. the Cua/Ccr ratio < 5%.